Unique substance warnings: Difference between revisions

>David Hedlund
Dosage: http://isomerdesign.com/PiHKAL/read.php?id=36&domain=pk
>David Hedlund
Genotype: * MDMA: A small percentage (1-10% depending on race & family history) are "slow metabolizers", who have low levels of a liver enzyme (P450 2D6) which metabolizes many drugs, including MDMA (as well as Prozac, DXM, and many other pharmaceuticals). These people may be more sensitive to MDMA, might require lower doses, and should be cautious.<ref>http://www.erowid.org/chemicals/mdma/mdma_basics.shtml</ref>
Line 20: Line 20:


===Genotype===
===Genotype===
* [[MDMA]]: A small percentage (1-10% depending on race & family history) are "slow metabolizers", who have low levels of a liver enzyme (P450 2D6) which metabolizes many drugs, including MDMA (as well as Prozac, DXM, and many other pharmaceuticals). These people may be more sensitive to MDMA, might require lower doses, and should be cautious.<ref>http://www.erowid.org/chemicals/mdma/mdma_basics.shtml</ref>
* [[THC]]: ''CYP2C9'' genotype affects THC sensitivity significantly: ''Subjects with the *3/*3 genotype had 3-fold higher THC levels in their blood than subjects with the *1/*1 genotype. Those subjects with one copy of each gene (*1/*3) had intermediate THC levels that were about 2-fold higher than subjects with *1/*1.''<ref>https://www.ncbi.nlm.nih.gov/books/NBK564166/</ref>
* [[THC]]: ''CYP2C9'' genotype affects THC sensitivity significantly: ''Subjects with the *3/*3 genotype had 3-fold higher THC levels in their blood than subjects with the *1/*1 genotype. Those subjects with one copy of each gene (*1/*3) had intermediate THC levels that were about 2-fold higher than subjects with *1/*1.''<ref>https://www.ncbi.nlm.nih.gov/books/NBK564166/</ref>


==References==
==References==
{{reflist}}
{{reflist}}